Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 73.95 CNY -3.08% Market Closed
Market Cap: 93.6B CNY
Have any thoughts about
Beijing Wantai Biological Pharmacy Enterprise Co Ltd?
Write Note

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Intangible Assets
ÂĄ642.7m
CAGR 3-Years
40%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Intangible Assets
ÂĄ982.3m
CAGR 3-Years
41%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Intangible Assets
ÂĄ987.4m
CAGR 3-Years
117%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Intangible Assets
ÂĄ8.5m
CAGR 3-Years
90%
CAGR 5-Years
112%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Intangible Assets
ÂĄ1.4B
CAGR 3-Years
4%
CAGR 5-Years
27%
CAGR 10-Years
18%
Imeik Technology Development Co Ltd
SZSE:300896
Intangible Assets
ÂĄ114.9m
CAGR 3-Years
123%
CAGR 5-Years
67%
CAGR 10-Years
N/A
No Stocks Found

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
93.8B CNY
Industry
Biotechnology

In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.

Intrinsic Value
62.75 CNY
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Intangible Assets?
Intangible Assets
642.7m CNY

Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Intangible Assets amounts to 642.7m CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
21%

Over the last year, the Intangible Assets growth was 93%. The average annual Intangible Assets growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 40% over the past three years , 21% over the past five years .

Back to Top